Discover
TELO
Telomir Pharmaceuticals, Inc.
1.30
2 x 0.92
2 x 1.63
bid
ask
+
0.02
1.56%
2 @ 04:00 PM
1.30 +0.00 (0.00%)
| Ytd | -2.26% | |
| 1y | 2.36% |
1.25
day range
1.35
1.05
52 week range
3.10
| Open | 1.28 | Prev Close | 1.28 | Low | 1.25 | High | 1.35 | Mkt Cap | 89.41M |
| Vol | 125.71K | Avg Vol | 153.33K | EPS | -0.29 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 5.77 | Inst. Own | 6.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.30 | 200-d Avg | 1.35 | 1yr Est | 12.15 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | 0 | -0.2 | N/A | N/A |
| 2024-08-13 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | 0 | -0.05 | N/A | N/A |
| 2024-05-13 | 2024-03 | 0 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | 0 | -0.23 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science. The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging. Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging. Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-02-12 | BAY SHORE TRUST | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Group Inc | 1.15M | 5.37M | 3.89% |
| 2024-09-29 | Blackrock Inc. | 366.88K | 1.71M | 1.24% |
| 2024-09-29 | Geode Capital Management, LLC | 238.74K | 1.11M | 0.81% |
| 2024-09-29 | Suncoast Equity Management | 51.19K | 238.56K | 0.17% |
| 2024-09-29 | Bank Of New York Mellon Corporation | 51.36K | 239.36K | 0.17% |
| 2024-09-29 | Northern Trust Corporation | 48.68K | 226.85K | 0.16% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 834.70K | 3.89M | 2.82% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 261.97K | 1.22M | 0.88% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 93.89K | 437.51K | 0.32% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 49.77K | 231.94K | 0.17% |
| 2024-10-30 | Fidelity Total Market Index Fund | 30.43K | 141.82K | 0.10% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 28.72K | 133.84K | 0.10% |